Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ixazomib + dexamethasone + lenalidomide + bevacizumab
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
The "IXO regimen" refers to a combination chemotherapy protocol that includes ixazomib (a proteasome inhibitor), dexamethasone (a corticosteroid), and lenalidomide (an immunomodulatory agent). When combined with bevacizumab—a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF)—the regimen is designed for enhanced anti-tumor activity. Bevacizumab works by binding to VEGF and inhibiting angiogenesis, thereby reducing tumor vascularization and growth[3][6][8]. This combination is primarily investigated or used in the treatment of various cancers where anti-angiogenic therapy may provide benefit.
- Brand names
- AvastinAlymsysJobevneMvasiVegzelmaZirabev
- Other names
- bevacizumab
02
Targets
GR (Glucocorticoid receptor)VEGFA (Vascular endothelial growth factor A)CRBN (Cereblon)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on ixazomib + dexamethasone + lenalidomide + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ixazomib + dexamethasone + lenalidomide + bevacizumab.